Benzinga's Top #PreMarket Gainers

shares climbed 21.25 percent to $35.55 in pre-market trading. On Thursday, KaloBios Pharmaceuticals announced agreement to acquire benznidazole program for the treatment of Chagas disease. The company also reported that it has raised $8.2 million in private placement.

shares rose 9.32 percent to $30.51 in pre-market trading after the company reported upbeat results for the third quarter.

shares rose 6.90 percent to $174.45 in pre-market trading after the company reported better-than-expected results for the third quarter.

shares surged 2.68 percent to $17.25 in pre-market trading after dropping 4.65 percent on Thursday.

gained 2.28 percent to $2.24 in pre-market trading after rising 1.39 percent on Thursday.